var popup="<div  class=\"common_popup\" class=\"hclasse\"><div class=\"common_popup_img\"></div><ol class=\"common_popup_txt\"><li>&nbsp;&nbsp;Résumés des Caractéristiques du Produit REKOVELLE<sup class=\"common_popup_sup\">&reg;</sup>. REKOVELLE<sup class=\"common_popup_sup\">&reg;</sup> 12 microgrammes/0,36 mL,<br/><span style=\"position: relative;top: -4px;\">&nbsp;&nbsp;REKOVELLE<sup class=\"common_popup_sup\">&reg;</sup> 36 microgrammes/1,08 mL et REKOVELLE<sup class=\"common_popup_sup\">&reg;</sup> 72 microgrammes/2,16 mL.</span></li><li>&nbsp;&nbsp;HAS - Commission de la transparence REKOVELLE<sup class=\"common_popup_sup\">&reg;</sup>. Avis du 5 avril 2017 et du 27 septembre 2017.</li><li>&nbsp;&nbsp;European Public Assessment Report 13 octobre 2016 REKOVELLE<sup class=\"common_popup_sup\">&reg;</sup>.</li><li>&nbsp;&nbsp;Andersen AN, <i>et al.</i> Individualized <i>versus</i> conventional ovarian stimulation for in vitro fertilization: a multicenter,<br/><span style=\"position: relative;top: -6px;\">&nbsp;&nbsp;randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertility and Sterility. 2017;107(2):387-96.</span></li><li>&nbsp;&nbsp;Mode d’emploi du stylo prérempli REKOVELLE<sup class=\"common_popup_sup\">&reg;</sup>.</li></ol><div class=\"common_popup_cross closeRefPopup\"></div></div>"
